As we previously reported, on August 2, 2017, AbbVie filed a complaint against Boehringer Ingelheim (BI) in the U.S. District Court for the District of Delaware regarding BI’s aBLA for a biosimilar version of AbbVie’s Humira® (adalimumab) product. We also reported last month that BI answered AbbVie’s complaint, and included counterclaims against AbbVie for invalidity…
